What's Happening?
Vivos Inc., a medical device company known for its RadioGel® Radionuclide Therapy™, is set to expand its manufacturing capabilities by establishing new production facilities in the U.S. and internationally. The company plans to open a domestic production site at the Applied Process Engineering Laboratory in Richland, Washington, and is in discussions to establish an international facility in India. These expansions aim to address previous concerns about relying on a single production site and are expected to be operational by 2026. The new facilities will produce Y-90 phosphate particles mixed with sterile hydrogel for individual patient doses, supporting the company's growth in both human and veterinary oncology applications.
Why It's Important?
The expansion of
Vivos Inc.'s manufacturing base is significant as it positions the company to meet increasing demand for its innovative cancer therapies. By diversifying its production sites, Vivos can enhance its production capacity, reduce shipping costs, and streamline logistics, which is crucial for its global market expansion. This move also reflects a strategic effort to mitigate risks associated with single-site dependency, ensuring a more robust supply chain. The establishment of these facilities is expected to support the company's long-term growth and improve access to its therapies, potentially benefiting patients worldwide.
What's Next?
Vivos Inc. will continue its production with the existing contract manufacturer in Texas until the new facilities are operational. The company is focused on completing the installation of manufacturing equipment and obtaining necessary licenses for the Richland facility. Concurrently, Vivos is finalizing agreements with potential partners in India to establish the international site. These steps are crucial for the company to achieve its goal of operational readiness by 2026, which will enable it to support higher production volumes and expand its market reach.
